Summit Therapeutics-Spon ADRSMMT
13F holders, Q4 2024 (December 31)7holders +5
5new positions
0sold out
$17.85avg. 13F price*
At the end of Q4 2024, 7 institutions reported holding Summit Therapeutics-Spon ADR (SMMT) in their 13F filings, up 5 from Q3 2024. 5 opened new positions and 0 sold out. The largest holders were Syon Capital LLC ($180K), Lindbrook Capital, LLC ($13K) and EverSource Wealth Advisors, LLC ($7K).
- Company
- Summit Therapeutics-Spon ADR
- CUSIP
- 86627R102
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $188K |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 10,543 shares bought and 10 shares sold, net +10,533 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Syon Capital LLC | 0.02% | New | 10,067 | $180K |
| Lindbrook Capital, LLC | 0.00% | No change | 755 | $13K |
| EverSource Wealth Advisors, LLC | 0.00% | New | 418 | $7K |
| Rothschild Investment LLC | 0.00% | Reduce -7.7% | 120 | $2K |
| Hexagon Capital Partners LLC | 0.00% | New | 45 | $803 |
| Farther Finance Advisors, LLC | 0.00% | New | 12 | $214 |
| Global Financial Private Client, LLC | 0.00% | New | 1 | $18 |
"% of holder's portfolio" is SMMT's weight in each manager's 13F, not the share of Summit Therapeutics-Spon ADR the manager owns.